Cargando…

Initial Experience of Sorafenib Neoadjuvant Therapy Combined with Retroperitoneoscopy in Treating T2 Large Renal Carcinoma

Objectives. To investigate the safety and feasibility of sorafenib neoadjuvant therapy combined with retroperitoneoscopic radical nephrectomy (RRN) in treating T2 large renal cell carcinoma (RCC). Methods. Retrospectively analyzed 5 cases (2 males and 3 females, aged 52–73 years) of T2 stage large R...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Chun-hua, Yuan, He-jia, Wang, Ke, Wu, Ji-tao, Liu, Qing-zuo, Yu, Sheng-qiang, Men, Chang-ping, Gao, Zhen-li, Wang, Jiahui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4573231/ https://www.ncbi.nlm.nih.gov/pubmed/26421296 http://dx.doi.org/10.1155/2015/609549

Ejemplares similares

Lower posterior mediastinal benign schwannoma successfully resected with retroperitoneoscopy using a transdiaphragmatic approach: A case report
por: Zhu, Dongdong, et al.
Publicado: (2018)

Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial
por: Procopio, G, et al.
Publicado: (2011)

Sorafenib Neoadjuvant Therapy in the Treatment of High Risk Renal Cell Carcinoma
por: Zhang, Yushi, et al.
Publicado: (2015)

Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis
por: Procopio, G, et al.
Publicado: (2013)

A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma
por: Larkin, J M G, et al.
Publicado: (2010)

Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib
por: Meng, Xiao-Chun, et al.
Publicado: (2018)

VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib
por: Kuiper, J L, et al.
Publicado: (2012)

Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib
por: Flaig, T W, et al.
Publicado: (2010)

Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial
por: Cella, D, et al.
Publicado: (2013)

Application of ureterorenoscope and flexible ureterorenoscope lithotripsy in removing calculus from extracorporeal living donor renal graft: a single-center experience
por: Lin, Chun-hua, et al.
Publicado: (2017)

Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study
por: Cai, Wen, et al.
Publicado: (2019)

Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer
por: Danilovic, Debora L. S., et al.
Publicado: (2018)

A Phase I Study of High-Dose Interleukin-2 With Sorafenib in Patients With Metastatic Renal Cell Carcinoma and Melanoma
por: Monk, Paul, et al.
Publicado: (2014)

Timing of surgery after neoadjuvant chemotherapy for gastric cancer: Impact on outcomes
por: Liu, Yi, et al.
Publicado: (2018)

Impact of sorafenib on epidural fibrosis: An immunohistochemical study
por: Tanriverdi, Osman, et al.
Publicado: (2018)

Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas
por: Schmidt, T, et al.
Publicado: (2014)

Application of renal-rotation techniques in retroperitoneoscopic partial nephrectomy
por: LIN, CHUN-HUA, et al.
Publicado: (2015)

Renal cell carcinoma and the use of sorafenib
por: Larkin, James MG, et al.
Publicado: (2006)

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial
por: Escudier, B, et al.
Publicado: (2014)

Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach
por: Kurokawa, Yukinori, et al.
Publicado: (2017)

Y-box binding protein 1 augments sorafenib resistance via the PI3K/Akt signaling pathway in hepatocellular carcinoma
por: Liu, Ting, et al.
Publicado: (2021)

Sorafenib in advanced melanoma: a critical role for pharmacokinetics?
por: Pécuchet, N, et al.
Publicado: (2012)

The Role of Redox-Regulating Enzymes in Inoperable Breast Cancers Treated with Neoadjuvant Chemotherapy
por: Roininen, Nelli, et al.
Publicado: (2017)

Polymorphism AGT2 (rs4762) is involved in the development of dermatologic events: Proof-of-concept in hepatocellular carcinoma patients treated with sorafenib
por: Sapena, Víctor, et al.
Publicado: (2022)

Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus
por: Zhang, Zi-Han, et al.
Publicado: (2017)

Predictive Immunohistochemical Markers Related to Drug Selection for Patients Treated with Sunitinib or Sorafenib for Metastatic Renal Cell Cancer
por: Ma, Xin, et al.
Publicado: (2016)

Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib
por: Pantaleo, Maria Abbondanza, et al.
Publicado: (2012)

Sorafenib in the management of metastatic renal cell carcinoma
por: Guevremont, C., et al.
Publicado: (2009)

Comparative Metabolomic Profiling of Hepatocellular Carcinoma Cells Treated with Sorafenib Monotherapy vs. Sorafenib-Everolimus Combination Therapy
por: Zheng, Jian-feng, et al.
Publicado: (2015)

Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma
por: Liu, Bao-Jiang, et al.
Publicado: (2020)

Neoadjuvant transcatheter arterial chemoembolization and systemic chemotherapy for the treatment of undifferentiated embryonal sarcoma of the liver in children
por: He, Min, et al.
Publicado: (2022)

Heme oxygenase-1 is a predictive biomarker for therapeutic targeting of advanced clear cell renal cell carcinoma treated with sorafenib or sunitinib
por: Zheng, Wan-Xiang, et al.
Publicado: (2015)

Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy
por: Gonzalez-Angulo, A M, et al.
Publicado: (2015)

Do pathological variables have prognostic significance in rectal adenocarcinoma treated with neoadjuvant chemoradiotherapy and surgery?
por: Reggiani Bonetti, Luca, et al.
Publicado: (2017)

Radiation Recall Dermatitis in Patients Treated with Sorafenib
por: Mehta, Keyur, et al.
Publicado: (2018)

Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
por: Ko, Yi-Ling, et al.
Publicado: (2020)

Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity
por: Lee, J-M, et al.
Publicado: (2010)

Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom
por: Palmer, D H, et al.
Publicado: (2013)

Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib
por: Di Fiore, F, et al.
Publicado: (2011)

Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis
por: Liu, Qinqin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ot0v62vphk5h5l4o5ga59qulgf